[go: up one dir, main page]

WO1995006659A1 - Nucleosides et oligonucleosides a fonction(s) amine - Google Patents

Nucleosides et oligonucleosides a fonction(s) amine Download PDF

Info

Publication number
WO1995006659A1
WO1995006659A1 PCT/US1994/010131 US9410131W WO9506659A1 WO 1995006659 A1 WO1995006659 A1 WO 1995006659A1 US 9410131 W US9410131 W US 9410131W WO 9506659 A1 WO9506659 A1 WO 9506659A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
mmol
uridine
dimethoxytrityl
oligomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1994/010131
Other languages
English (en)
Inventor
Phillip Dan Cook
Muthiah Manoharan
Charles J. Guinosso
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/117,363 external-priority patent/US6783931B1/en
Priority to EP94928048A priority Critical patent/EP0728139B1/fr
Priority to DE69433036T priority patent/DE69433036T2/de
Priority to AU77233/94A priority patent/AU679566B2/en
Priority to CA002170869A priority patent/CA2170869C/fr
Priority to US08/602,862 priority patent/US7037646B1/en
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Priority to JP50832695A priority patent/JP3484197B2/ja
Priority to AT94928048T priority patent/ATE247128T1/de
Publication of WO1995006659A1 publication Critical patent/WO1995006659A1/fr
Anticipated expiration legal-status Critical
Priority to US09/435,806 priority patent/US6653458B1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1133—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against herpetoviridae, e.g. HSV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3527—Other alkyl chain

Definitions

  • nucleosides oligonucleotides and oligonucleosides functionalized to include alkylamino functionality, and derivatives thereof.
  • the compounds of the invention further include steroids, reporter molecules, reporter enzymes, lipophilic molecules, peptides or proteins attached to the nucleosides through the alkylamino group.
  • RNA messenger RNA directs protein synthesis.
  • Antisense methodology is the complementary hybridization of relatively short oligonucleotides to mRNA or DNA such that the normal, essential functions of these intracellular nucleic acids are disrupted.
  • Hybridization is the sequence-specific hydrogen bonding via Watson-Crick base pairs of oligonucleo- tides to RNA or single-stranded DNA. Such base pairs are said to be complementary to one another.
  • hybridization arrest denotes the terminating event in which the oligonucleotide inhibitor binds to the target nucleic acid and thus prevents, by simple steric hindrance, the binding of essential proteins, most often ribosomes, to the nucleic acid.
  • Methyl phosphonate oligonucleotides (Miller, et al., Anti-Cancer Drug Design 1987, 2, 117) and ⁇ -anomer oligonucleotides are the two most extensively studied antisense agents which are thought to disrupt nucleic acid function by hybridization arrest.
  • the second type of terminating event for antisense oligonucleotides involves the enzymatic cleavage of the targeted RNA by intracellular RNase H.
  • a 2' -deoxyribofuranosyl oligonucleotide or oligonucleotide analog hybridizes with the targeted RNA and this duplex activates the RNase H enzyme to cleave the RNA strand, thus destroying the normal function of the RNA.
  • Phosphorothioate oligonucleotides are the most prominent example of an antisense agent that operates by this type of antisense terminating event.
  • oligonucleotides and oligonucleotide analogs as antisense agents for diagnostics, research reagents and potential therapeutic purposes.
  • the antisense oligonucleotides and oligonucleotide analogs must be transported across cell membranes or taken up by cells to express activity.
  • One method for increasing membrane or cellular transport is by the attachment of a pendant lipophilic group.
  • a cholesteryl group was attached to the inter-nucleotide linkage between the first and second nucleotides (from the 3' terminus) of an oligonucleotide.
  • This work is disclosed in United States patent 4,958,013 and further by Letsinger, et al . , Proc. Natl . Acad. Sci . USA 1989, 86, 6553.
  • the aromatic intercalating agent anthraquinone was attached to the 2' position of a sugar fragment of an oligonucleotide as reported by Yamana, et al . , Bioconjugate Chem . 1990, 1 , 319.
  • the same researchers placed pyrene-1-methyl at the 2' position of a sugar (Yamana et. al . , Tetrahedron Lett . 1991, 32, 6347).
  • oligonucleotide-poly (L-lysine) conjugates are described in European Patent application 87109348.0.
  • lysine residue was coupled to a 5' or 3' phosphate of the 5' or 3' terminal nucleotide of the oligonucleotide.
  • a disulfide linkage has also been utilized at the 3' terminus of an oligonucleotide to link a peptide to the oligonucleotide as is described by Corey, et al . , Science 1987, 238, 1401; Zuckermann, et al . , J. Am. Chem. Soc . 1988, 110, 1614; and Corey, et al . , J. Am. Chem. Soc . 1989, 111 , 8524. Nelson, et al . , Nuc. Acids Res .
  • a similar commercial reagent for linking to the 5'-terminus of an oligonucleotide is 5'-Amino-Modifier C6.
  • These reagents are available from Glen Research Corporation (Sterling, VA). These compounds or similar ones were utilized by Krieg, et al . , Antisense Research and Development 1991, 1, 161 to link fluorescein to the 5'-terminus of an oligonucleotide.
  • Other compounds of interest have also been linked to the 3' -terminus of an oligonucleotide. Asseline, et al . , Proc. Natl . Acad. Sci .
  • the invention provides nucleosides having base portions and ribofuranosyl sugar portions. Such nucleosides bear at a 2'-O-position, a 3'-O-position, or a 5'-O-position a substituent having formula:
  • R A is alkyl having from 1 to about 10 carbon atoms or R A is (CH 2 -CH 2 -Q-) x ;
  • R 1a and R 1b independently, are H, R 2 , or an amine protecting group, have formula C(X)-R 2 , C(X)-R A -R 2 , C(X)-Q-R A -R 2 ,
  • R 2 includes a steroid molecule, a reporter molecule, a lipophilic molecule, a reporter enzyme, a peptide, a protein, or has formula -Q-(CH 2 CH 2 -Q-) x -R 3 ;
  • X is O or S
  • each Q is, independently, is NH, O, or S;
  • x is 1 to about 200
  • R 3 is H, R A , C(O)OH, C(O)OR A , C(O)R 4 , R A -N 3 , R A -NH 2 , or R A -SH;
  • R 4 is Cl, Br, I, SO 2 R s or has structure: ;
  • n 2 to 7;
  • R 5 is alkyl having 1 to about 10 carbon atoms.
  • the invention provides oligonucleotides and oligonucleosides comprising a plurality of linked nucleosides, wherein each nucleoside includes a ribofuranosyl sugar portion and a base portion and at least one (preferably more than one) of the nucleosides bears at a 2'-O-position, a
  • the invention provides methods for preparing oligonucleotides and oligonucleosides comprising the steps of contacting nucleosides according to the invention for a time and under reaction conditions effective to form a covalent bond therebetween.
  • at least one of the nucleosides bears a phosphoramidate group at its 2'-O-position or at its 3'-O-position.
  • compounds according to the invention are prepared by contacting a nucleoside, oligonucleotide or oligonucleoside with derivatizing reagents.
  • a nucleoside, oligonucleotide or oligonucleoside bearing a 2'-hydroxy group, a 3'-hydroxy group, or a 5'-hydroxy group under basic conditions with a compound having formula L 1 -R A -N(R 1a )(R 1b ) wherein L 1 is a leaving group such as a halogen and at least one of R 1a and R 1b is an amine protecting group.
  • the present invention also provides methods for inhibiting the expression of particular genes in the cells of an organism, comprising administering to said organism a compound according to the invention. Also provided are methods for inhibiting transcription and/or replication of particular genes or for inducing degradation of particular regions of double stranded DNA in cells of an organism by administering to said organism a compound of the invention. Further provided are methods for killing cells or virus by contacting said cells or virus with a compound of the invention.
  • the compound can be included in a composition that further includes an inert carrier for the compound.
  • nucleosides oligonucleotides and oligonucleosides containing alkylamino chemical functionality.
  • the nucleoside subunits can be "natural” or “synthetic” moieties.
  • Each nucleoside is formed from a naturally occurring or synthetic base and a naturally occurring or synthetic pentofuranosyl sugar group.
  • oligonucleotide refers to a polynucleotide formed from a plurality of linked nucleotide units.
  • the nucleotides units each include a nucleoside unit.
  • oligonucleoside refers to a plurality of nucleoside units that are linked together.
  • oligonucleoside can be considered to be inclusive of oligonucleotides (i.e., nucleosides linked together via phosphate linking groups).
  • oligonucleoside also refers to a plurality of nucleosides that are linked together via linkages other than phosphate linkages.
  • the term “oligonucleoside” thus effectively includes naturally occurring species or synthetic species formed from naturally occurring subunits.
  • oligonucleoside will be used as encompassing both phosphate linked (oligonucleotides) and non-phosphate linked polynucleoside species.
  • Oligonucleosides according to the invention also can include modified subunits. Representative modifications include modification of a heterocyclic base portion of a nucleoside or a sugar portion of a nucleoside. Exemplary modifications are disclosed in the following United States Patent Applications: Serial No. 463,358, filed January 11, 1990, entitled Compositions And Methods For Detecting And Modulating RNA Activity; Serial No. 566,977, filed August 13, 1990, entitled Sugar Modified Oligonucleotides That Detect And Modulate Gene Expression; Serial No. 558,663, filed July 27, 1990, entitled Novel Polyamine Conjugated Oligonucleotides; Serial No.
  • oligonucleoside thus refers to structures that include modified portions, be they modified sugar moieties or modified base moieties, that function similarly to natural bases and natural sugars.
  • Representative modified bases include deaza or aza purines and pyrimidines used in place of natural purine and pyrimidine bases; pyrimidines having substituent groups at the 5 or 6 position; and purines having altered or replacement substituent groups at the 2, 6 or 8 positions.
  • Representative modified sugars include carbocyclic or acyclic sugars, sugars having substituent groups at their 2' position, and sugars having substituents in place of one or more hydrogen atoms of the sugar. Other altered base moieties and altered sugar moieties are disclosed in United States Patent 3,687,808 and PCT application PCT/US89/02323.
  • Altered base moieties or altered sugar moieties also include other modifications consistent with the spirit of this invention.
  • Such oligonucleosides are best described as being structurally distinguishable from yet functionally interchangeable with naturally occurring or synthetic wild type oligonucleotides. All such oligonucleosides are comprehended by this invention so long as they function effectively to mimic the structure of a desired RNA or DNA strand.
  • the oligonucleosides of the invention preferably comprise from about 10 to about 30 subunits. It is more preferred that such oligonucleosides comprise from about 15 to about 25 subunits.
  • a subunit is a base and sugar combination suitably bound to adjacent subunits through, for example, a phosphorous- containing ⁇ e . g. , phosphodiester) linkage or some other linking moiety.
  • the nucleosides need not be linked in any particular manner, so long as they are covalently bound. Exemplary linkages are those between the 3'- and 5' -positions or 2'- and 5' -positions of adjacent nucleosides.
  • linking moieties are disclosed in the following references: Beaucage, et al . , Tetrahedron 1992, 48, 2223 and references cited therein; and United States Patent Applications: Serial No. 703,619, filed May 21, 1991; Serial No. 903,160, filed June 24, 1992; Serial No. 039,979, filed March 20, 1993; Serial No. 039,846, filed March 30, 1993; and Serial No. 040,933, filed March 31, 1993.
  • RNA or DNA portion which is to be modulated using oligonucleosides of the invention be preselected to comprise that portion of DNA or RNA which codes for the protein whose formation or activity is to be modulated.
  • the targeting portion of the composition to be employed is, thus, selected to be complementary to the preselected portion of DNA or RNA, that is, to be an antisense oligonucleoside for that portion.
  • the compounds of the invention hybridize to HIV mRNA encoding the tat protein, or to the TAR region of HIV mRNA. In another preferred embodiment, the compounds mimic the secondary structure of the TAR region of HIV mRNA, and by doing so bind the tat protein.
  • Other preferred compounds are complementary to sequences for herpes, papilloma and other viruses.
  • the nucleosides and oligonucleosides of the invention can be used in diagnostics, therapeutics and as research reagents and kits. They can be used in pharmaceutical compositions by including a suitable pharmaceutically acceptable diluent or carrier. They further can be used for treating organisms having a disease characterized by the undesired production of a protein. The organism should be contacted with an oligonucleotide having a sequence that is capable of specifically hybridizing with a strand of nucleic acid coding for the undesirable protein. Treatments of this type can be practiced on a variety of organisms ranging from unicellular prokaryotic and eukaryotic organisms to multicellular eukaryotic organisms.
  • Any organism that utilizes DNA-RNA transcription or RNA-protein translation as a fundamental part of its hereditary, metabolic or cellular control is susceptible to therapeutic and/or prophylactic treatment in accordance with the invention. Seemingly diverse organisms such as bacteria, yeast, protozoa, algae, all plants and all higher animal forms, including warm-blooded animals, can be treated. Further, since each cell of multicellular eukaryotes can be treated since they include both DNA-RNA transcription and RNA-protein translation as integral parts of their cellular activity. Many of the organelles (e . g. , mitochondria and chloroplasts) of eukaryotic cells also include transcription and translation mechanisms.
  • organelles e . g. , mitochondria and chloroplasts
  • single cells, cellular populations or organelles can also be included within the definition of organisms that can be treated with therapeutic or diagnostic oligonucleotides .
  • therapeutics is meant to include the eradication of a disease state, by killing an organism or by control of erratic or harmful cellular growth or expression.
  • the present invention is directed to nucleosides and oligonucleosides that bear at least one amine- containing substituent at a position.
  • substituents preferably have formula -R A -N(R 1a ) (R 1b ) and are appended at 2'-O-, 3'-O-, and/or 5'-O-positions.
  • R A is an alkyl moiety independently selected to having 1 to about 10 carbon atoms or R A is a polyether, a polythioether or polyalkylamine .
  • alkyl is intended to include straight chain and branched hydrocarbons.
  • the preferred length of these hydrocarbons is 1 to about 7 carbon atoms, more preferably 3 or 4 carbon atoms.
  • R 1a and R 1b according to the invention are H, R 2 , an amine protecting group, have formula C(X)-R 2 , C(X)-R A -R 2 , C(X)-Q-R A -R 2 , C(X)-Q-R 2 , or, together, complete a cycloalkyl or cycloaryl moiety having two to six carbon atoms and one or two nitrogen atoms such as an imidazole moiety.
  • R 1a and R 1b according to the invention are H, R A , R 2 , an amine protecting group, or have formula C(X)-R 2 , C(X)-R A -R 2 , C(X)-Q-R A -R 2 , C(X)-Q-R 2 .
  • Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as amine groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. See, e . g. , Greene and Wuts, Protective Groups in Organic Synthesis, 2d edition, John Wiley & Sons, New York, 1991.
  • amine protecting groups are known in the art, including, but not limited to: phthalimide (PHTH), trifluoroacetate (triflate), allyloxycarbonyl (Alloc), benzyloxycarbonyl (CBz), chlorobenzyloxycarbonyl, t-butyloxycarbonyl (Boc), fluorenylmethoxycarbonyl (Fmoc), and isonicotinyloxycarbonyl (i-Noc) groups, ( see, e. g. , Veber and Hirschmann, et al . , J. Org. Chem. 1977, 42, 3286 and Atherton, et al .
  • R 2 can include a steroid molecule, a reporter molecule, a lipophilic molecule, a reporter enzyme, a peptide, a protein (i.e., a substituent consisting essentially of same), or a molecule having formula -Q-(CH 2 CH 2 -Q-) x -R 3 .
  • reporter molecule and “reporter enzyme” are inclusive of those molecules or enzymes that have physical or chemical properties that allow them to be identified in gels, fluids, whole cellular systems, broken cellular systems and the like utilizing physical properties such as spectroscopy, radioactivity, colorimetric assays, fluorescence, and specific binding.
  • Steroids include those chemical compounds that contain a perhydro-1,2-cyclop-ntanophenanthrene ring system.
  • Proteins and peptides are utilized in their usual sense as polymers of amino acids. Normally peptides comprise such polymers that contain a smaller number of amino acids per unit molecule than do the proteins.
  • Lipophilic molecules include naturally-occurring and synthetic aromatic and non-aromatic moieties such as fatty acids, esters, alcohols and other lipid molecules, substituted aromatic groups such as dinitrophenyl groups, cage structures such as adamantane and buckminsterfullerenes, and aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene , naphthalene , pyrene , chrysene , and naphthacene .
  • aromatic hydrocarbons such as benzene, perylene, phenanthrene, anthracene , naphthalene , pyrene , chrysene , and naphthacene .
  • Particularly useful as steroid molecules are the bile acids including cholic acid, deoxycholic acid and dehydrocholic acid; steroids including cortisone, digoxigenin, testosterone and cholesterol and even cationic steroids such as cortisone having a trimethylaminomethyl hydrazide group attached via a double bond at the 3 position of the cortisone rings.
  • Particularly useful as reporter molecules are biotin, dinitrophenyl, and fluorescein dyes.
  • Particularly useful as lipophilic molecules are alicyclic hydrocarbons, saturated and unsaturated fatty acids, waxes, terpenes and polyalicyclic hydrocarbons including adamantane and buckminsterfullerenes .
  • reporter enzymes are alkaline phosphatase and horseradish peroxidase.
  • Particularly useful as peptides and proteins are sequence-specific peptides and proteins including phosphodiesterase, peroxidase, phosphatase and nuclease proteins.
  • Such peptides and proteins include SV40 peptide, RNaseA, RNase H and Staphylococcal nuclease.
  • Particularly useful as terpenoids are vitamin A, retinoic acid, retinal and dehydroretinol.
  • R 2 also can have formula -Q-(CH 2 CH 2 -Q-) x -R 3 , where Q is 0, S, or NH.
  • Subscript x can be 1 to about 200, preferably about 20 to about 150, more preferably about 10 to about 50.
  • R 3 can be H, R A , C(O)OH, C(O)OR A , C(O)R 4 , R A -N 3 , R A -NH 2 or R A -SH where R 4 is F, Cl, Br, I, SO 2 R 5 or a small thio-containing heterocycle having structure
  • Oligonucleosides according to the invention can be assembled in solution or through solid-phase reactions, for example, on a suitable DNA synthesizer utilizing nucleosides according to the invention and/or standard nucleotide precursors.
  • the nucleosides and nucleotide precursors can already bear alkylamino groups or can be later modified to bear such groups.
  • compounds according to the invention are prepared by, for example, reacting nucleosides bearing at least one free 2'-, 3'-, or 5 '-hydroxyl group under basic conditions with a compound having formula L 1 -(CH 2 ) n -N(R 1a ) (R 1b ) where L 2 is a leaving group and at least one of R 1a and R 1b is an amine protecting group. Displacement of the leaving group through nucleophilic attack of an oxygen anion produces the desired amine derivative.
  • Leaving groups according to the invention include but are not limited to halogen, alkyl sulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted arylsulfonyl, hetercyclcosulfonyl or trichloroacetimidate.
  • a more preferred group includes chloro, fluoro, bromo, iodo, p- (2,4-dinitroanilino)benzenesulfonyl, benzenesulfonyl, methylsulfonyl (mesylate), p-methylbenzenesulfonyl (tosylate), p-bromobenzenesulfonyl, trifluoromethylsulfonyl (triflate), trichloroacetimidate, acyloxy, 2,2,2-trifluoroethanesulfonyl, imidazoleysulfonyl, and 2,4,6-trichlorophenyl, with bromo being preferred.
  • nucleosides can be assembled into an oligonucleosides according to known techniques. See, e . g. , Beaucage, et al . , Tetrahedron 1992, 48, 2223.
  • Oligonucleosides according to the invention also can be prepared by assembling an oligonucleoside and appending alkyl- amino functionality thereto.
  • oligonucleosides having free hydroxyl groups can be assembled according to known techniques and then reacted with a reagent having formula L 1 - (CH 2 ) n -N(R 1a ) (R 1b ).
  • greater selectivity can be achieved in terms of placement of alkylamino functionality within an oligonucleoside by introducing such functionality, as discussed above, on selected nucleosides and then using both the selected nucleosides and other nucleosides to construct an oligonucleoside.
  • an oligonucleoside bearing one or more groups having formula -R A -N(R 1a )(R 1b ) wherein at least one of R 1a and R 1b is a protecting group is treated with reagents effective to remove the protecting group.
  • Preferred electrophillic moieties include cholesteryl-3-hemisuccinate-N-hydroxy succinimide ester, pyrene-1-butyric acid-N-hydroxy succinimide ester and polyethylene glycol-propionic acid-N-hydroxy succimide ester.
  • the invention first builds the desired linked nucleoside sequence in the normal manner on the DNA synthesizer.
  • One or more (preferably two or more) of the linked nucleosides are then functionalized or derivatized with the lipophilic steroid, reporter molecule, lipophilic molecule, reporter enzyme, peptide or protein.
  • Oligonucleotide synthesis was carried out in either an ABI 390B or an ABI 394 synthesizer employing the standard synthesis cycles with an extended coupling time of 10 minutes during coupling of Compound 2 into the oligonucleotide sequence. Coupling efficiency of greater than 98% was observed.
  • Oligomer 9 5' TA * G 3';
  • Oligomer 10 5' CCA * G 3' ;
  • Oligomer 11 (SEQ ID NO:1) : 5' GGC TGA * CTG CG 3 ' ;
  • Oligomer 12 (SEQ ID NO: 2) : CTG TCT CCA * TCC TCT TCA CT;
  • Oligomers 12 and 13 are antisense compounds to the E2 region of the bovine papilloma virus-1 (BPV-1). Oligomers 12 and 13 have the same sequence as Oligomer 3 in Application Serial Number 782,374, except for the 2' modification.
  • the oligonucleotides were synthesized in either a 10 ⁇ mol scale or a 3 ⁇ 1 ⁇ mol scale in the "Trityl-On" mode. Standard deprotection conditions (30%
  • oligonucleotides were purified by reverse phase HPLC (Waters Delta-Pak C 4 15 ⁇ m, 300A, 25 ⁇ 100 mm column equipped with a guard column of the same material). They were detritylated and further purified by size exclusion using a Sephadex G-25 column. NMR analyses by both proton and phosphorus NMR confirmed the expected structure for the Oligomers 9 and 10.
  • Oligomer 14 (SEQ ID NO: 3) :
  • Oligomer 15 (SEQ ID NO:4) :
  • Oligomer 14 is an antisense compound directed to the E2 region of the bovine papilloma virus-1 (BPV-1). Oligomers 15 and 16 are antisense compounds to ICAM. Oligomer 14 has the same sequence as Oligomer 3 in Application Serial Number 782,374, except for the 2' modification whereas Oligomers 15 and 16 have the same sequence as Oligomer 4 in Application Serial Number 782,374 except for the 2' modification.
  • BPV-1 bovine papilloma virus-1
  • Oligomer 17 (SEQ ID NO: 24) : CCA A*GC CUC AGA; and Oligomer 18 (SEQ ID NO: 25) : CCA GGC UCA GA*T
  • A* represents a nucleotide functionalized to incorporate a pentyl-N-phthalimido functionality and where the remaining nucleotides except the 3 '-terminus nucleotide are each 2'-O-methyl derivatized nucleotides.
  • the 3 '-terminus nucleotide in both Oligomers 17 and 18 is a 2'-deoxy nucleotide. Both Oligomers 17 and 18 are antisense compounds to the HIV-1 TAR region.
  • the oligonucleotides were synthesized as per the method of Example 6 in Application Serial Number 782,374 (utilizing Compound 2 thereof) for introduction of the nucleotides containing the pentyl-N-phthalimido functionality and appropriate 2-O-methyl phosphoramidite nucleotides from Chemgenes Inc. (Needham, MA) for the remaining RNA nucleotides.
  • the 3 '-terminus terminal 2'-deoxy nucleotides were standard phosphoamidites utilized for the DNA synthesizer.
  • the oligonucleotides were deprotected and purified as per the method of Example 1(B).
  • Oligomer 19 (SEQ ID NO: 5) : CTG TCT CCA * TCC TCT TCA CT wherein A * represents a nucleotide functionalized to incorporate a biotin functionality linked via a 2'-O-pentylamino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below.
  • a * represents nucleotides functionalized to incorporate a biotin functionality linked via a 2 ' -O-pentyl-amino linking group to the 2' position of the designated nucleotide.
  • HPLC retention times for this product (and its accompanying singly labeled products) are shown in Table 1 below.
  • a 1M Na 2 CO 3 /1M NaHCO 3 buffer (pH 9.0) was prepared by adding 1M NaHCO 3 to 1 M Na 2 CO 3 . A 200 ⁇ l portion of this buffer was added to 10 O.D. units of Oligomer 12 (see, Example 1) in a microfuge tube. A 10 mg portion of fluorescein-isocyanate in 500 ⁇ l DMF was added to give a 0.05 M solution. A 100 ⁇ l portion of the fluorescein solution was added to the oligonucleotide solution in the microfuge tube. The tube was covered with aluminum foil and let stand overnight.
  • the reaction mixture was applied to a Sephadex G-25 column (0.7 ⁇ 20 cm) that had been equilibrated with 25% (v/v) ethyl alcohol in water.
  • the column was eluted with the same solvent.
  • Product migration could be seen as a yellow band well separated from dark yellow band of the excess fluorescein reagent.
  • the fractions showing absorption at 260 nm and 485 nm were combined and purified by HPLC as per the purification procedure of Example 2(A)(1).
  • Analytical HPLC indicated 81% of the desired doubly functionalized oligonucleotide.
  • the product was lyophilized and desalted on Sephadex to give the oligonucleotide :
  • Oligomer 21 [(SEQ ID NO: 9)]: CTG TCT CCA * TCC TCT TCA CT wherein A * represents a nucleotide functionalized to incorporate a fluorescein functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide. HPLC retention times are shown in Table 1 below. 2. Multiple Site Modification
  • a 10 O.D. unit (A 260 ) portion of Oligomer 13 was dissolved in 300 ⁇ l of the 1M Na 2 HCO 3 / 1M Na 2 CO 2 buffer of Example 2(B) (1) and 200 ⁇ l of the fluorescein-isothiocyanate stock solution of Example 2(B) (1) was added. The resulting solution was treated as per Example 2 (B) (1).
  • Analytical HPLC indicated 61% of doubly labeled product and 38% of singly labeled products. Work up of the reaction gave the oligonucleotide :
  • a * represents nucleotides functionalized to incorporate a fluorescein functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide.
  • HPLC retention times are shown in Table 1 below.
  • a 10 O.D. unit (A 260 ) portion of Oligomer 12 was treated with cholic acid-NHS ester (Compound 1 in Application Serial Number 782,374, 5 mg, 9.9 ⁇ mols) in 200 ⁇ l of 0.2 M NaHCO 3 buffer/ 40 ⁇ l DMF.
  • the reaction mixture was heated for 16 hours at 45°C.
  • the product was isolated as per the method of Example 2(B) (1).
  • a * represents a nucleotide functionalized to incorporate a cholic acid functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide.
  • HPLC retention times are shown in Table 1 below.
  • Oligomer 24 CTG TCT CCA * TCC TCT TCA * CT
  • a * represents nucleotides functionalized to incorporate a cholic acid functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide.
  • HPLC retention times are shown in Table 1 below.
  • a 10 O.D. unit (A 260 ) portion of Oligomer 12 (see, Example 1) was treated with digoxigenin-3-O-methylcarbonyl- ⁇ -aminocaproic N-hydroxy succinimide ester (Boehringer Mannheim Corporation, Indianapolis, IN) in 200 ⁇ l of 0.1 M borate pH 8.3 buffer/ 40 ⁇ l DMF. The reaction mixture was let stand overnight. The product was isolated as per the method of Example 2(A) (1). Work up of the reaction gave the oligonucleotide:
  • Oligomer 25 CTG TCT CCA * TCC TCT TCA CT
  • a * represents a nucleotide functionalized to incorporate a digoxigenin functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide.
  • HPLC retention times are shown in Table 1 below.
  • a * represents nucleotides functionalized to incorporate a cholic acid functionality linked via a 2'-O-pentyl-amino linking group to the 2' position of the designated nucleotide.
  • HPLC retention times are shown in Table 1 below. TABLE 1
  • Oligomer 20 2 24.16 a 25.19 b
  • Oligonucleotides of the invention were digested with snake venom phosphodiesterase and calf-intestine alkaline phosphatase to their individual nucleosides. After digestion, the nucleoside composition was analyzed by HPLC. The HPLC analysis established that functionalized nucleotide compounds having the tethered 2'-amino moiety thereon were correctly incorporated into the oligonucleotide.
  • Snake venom phosphodiesterase [Boehringer-Mannheim cat . #108260, 1 mg (1.5 units) /0.5 ml] and alkaline phosphatase from calf intestine (1 unit/microliter, Boehringer-Mannheim cat.
  • Tris-HCl buffer pH 7.2, 50 mM
  • oligonucleotides were used to digest the oligonucleotides to their component nucleosides.
  • To 0.5 O.D. units of oligonucleotide in 50 ⁇ l buffer (nearly 40 ⁇ M final concentration for a 20 mer) was added 5 ⁇ l of snake venom phosphodiesterase (nearly 0.3 units/mL, final concentration) and 10 ⁇ l of alkaline phosphatase (app. 150 units/mL, final concentration).
  • the reaction mixture was incubated at 37°C for 3 hours. Following incubation, the reaction mixture was analyzed by HPLC using a reverse phase analytical column (app.
  • Oligomer 12 9 1 8 1 1 Oligomer 13 9 1 8 2 * Nucleoside having 2'-O-linker attached thereto; and * * Corrected to whole numbers.
  • the relative ability of oligonucleotides to bind to their complementary strand is compared by determining the melting temperature of the hybridization complex of the oligonucleotide and its complementary strand.
  • the melting temperature (Tm) a characteristic physical property of double helices, denotes the temperature in degrees centigrade at which 50% helical versus coil (un-hybridized) forms are present. Tm is measured by using the UV spectrum to determine the formation and breakdown (melting) of hybridization. Base stacking, which occurs during hybridization, is accompanied by a reduction in UV absorption (hypochromicity). Consequently a reduction in UV absorption indicates a higher T m . The higher the Tm, the greater the strength of the binding of the strands. Non-Watson-Crick base pairing has a strong destabilizing effect on the Tm. Consequently, absolute fidelity of base pairing is necessary to have optimal binding of an antisense oligonucleotide to its targeted RNA.
  • a series of oligonucleotides were synthesized utilizing standard synthetic procedures (for un-functionalized oligonucleotides) or the procedure of Example 3 (A) in Application Serial Number 782,374 for oligonucleotides having a 5' -terminus amino linker bearing oligonucleotide or the procedure of Example 3(B) in Application Serial Number 782,374 for 5' -terminus cholic acid-bearing oligonucleotides.
  • Each of the oligonucleotides had the following 5-LO antisense sequence: 5' TCC AGG TGT CCG CAT C 3' (SEQ ID NO: 6). The nucleotides were synthesized on a 1.0 ⁇ mol scale.
  • Oligomer 32 was the parent compound having normal phosphodiester internucleotide linkages.
  • Oligomer 33 incorporated phosphorothioate inter-nucleotide linkages in the basic oligonucleotide sequence.
  • Oligomer 34 is a an intermediate oligonucleotide having a 5'-aminolink at the 5'-terminus of the basic oligonucleotide sequence and Oligomer 35 was a similar 5'-aminolink compound incorporating phosphorothioate inter-nucleotide linkages.
  • Oligomer 36 is a 5'-terminus cholic acid conjugate of the basic phosphodiester oligonucleotide sequence while Oligomer 37 is a similar 5'-cholic acid conjugate incorporating phosphorothioate inter-nucleotide linkages.
  • Oligomers 32 and 33 were synthesized in a "TritylOn" mode and were purified by HPLC.
  • Oligomers 34 and 35 were synthesized as per Example 30(A) in Application Serial Number 782,374 without or with Beaucage reagent treatment, to yield phosphodiester or phosphorothioate inter-nucleotide linkages, respectively.
  • Oligomers 36 and 37 were prepared from samples of Oligomers 34 and 35, respectively, utilizing a solution of cholic acid N-hydroxysuccinimide ester (Compound 1) 1 dissolved in DMF as per Example 3 (B) in Application Serial Number 782,374. Oligomers 36 and 37 were purified by HPLC. The products were concentrated and desalted in a Sephadex G-25 column. Gel electrophoresis analyses also confirmed a pure product with the pure conjugate moving slower than the parent oligonucleotide or 5' -amino functionalized oligonucleotide.
  • test oligonucleotides either the phosphodiester, phosphorothioate, cholic acid conjugated phosphodiester, cholic acid conjugated phosphorothioate or 5'-aminolink intermediate phosphodiester or phosphorothioate oligonucleotides of the invention or otherwise
  • complementary DNA or RNA oligonucleotides were incubated at a standard concentration of 4 ⁇ M for each oligonucleotide in buffer (100 mM NaCl, 10 mM Na-phosphate, pH 7.0, 0.1 mM EDTA). Samples were heated to 90 degrees C and the initial absorbance taken using a Guilford Response II spectrophotometer (Corning).
  • Oligomer 38 (SEQ ID NO: 7) : GGA * CCG GA * A * GGT A * CG A * G wherein A * represents a nucleotide functionalized to incorporate a pentylamino functionality at its 2' -position was synthesized in a one micromole scale utilizing the method of Example 1 (B). The oligonucleotide was purified by reverse phase HPLC, detritylated and desalted on Sephadex G-25. PAGE gel analysis showed a single band. A further oligonucleotide, Oligomer 39, having the same sequence but without any 2'-O-amino linker was synthesis in a standard manner.
  • Oligomer 41 (SEQ ID NO: 9) : CCU GGC CUU CCA UGC UC. b. Melting Analysis
  • the change in Tm's between the strand having 2 '-amino linkers thereon and the unmodified strand is 1.1 degrees (0.22 change per modification).
  • the change is -6.1 degrees (-1.2 change per modification).
  • the 2'-amino linker- containing strand has a stabilizing effect upon hybridization with RNA and a destabilizing effect upon hybridization with DNA.
  • Oligomer 42 CTG TCT CCA TCC TCT TCA CT
  • Oligomer 42 served as the positive control and standard for the assay.
  • Oligomer 3 (from Example 4 in Application Serial Number 782,374) served as a second test compound. It has the same basic sequence except it is a phosphorothioate oligonucleotide and further it has a cholic acid moiety conjugated at the 3'-end of the oligonucleotide.
  • Oligomer 2 (from Example 2 in Application Serial Number 782,374) served as a third test compound.
  • Oligomer 5 (from Example 5 in Application Serial Number 782,374) served as a fourth test compound. Once again it has the same sequence, is a phosphorothioate oligonucleotide and it has a cholic acid moiety conjugated at both the 3 '-end and 5' -end.
  • a fifth test compound was a phosphorothioate oligonucleotide with no significant sequence homology with BPV-1.
  • a sixth test compound was a further phosphorothioate oligonucleotide with no significant sequence homology with BPV-1.
  • the last test compound, the seventh test compound was a phosphorothioate oligonucleotide with cholic acid conjugated to the 3 '-end but having no significant sequence homology with BPV-1.
  • Compounds five, six and seven served as negative controls for the assay.
  • Oligomer 43 (SEQ ID NO: 10) : CCC AGG CUC AGA where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group served as the basic test compound.
  • Oligomer 44 5'-CHA CCC AGG CUC AGA
  • CHA represents cholic acid and where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group, was also of the same sequence as the first test compound.
  • This second test compound included cholic acid conjugated to its 5' -end and was prepared as per the method of Example 3 in Application Serial Number 782,374 utilizing 2'-O-methyl phosphoramidite intermediates as identified in Example 1(C).
  • Oligomer 45 CCC AGG CUC AGA 3' -CHA
  • CHA represents cholic acid and where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group was also of the same sequence as the first test compound.
  • the third test compound included cholic acid conjugated to its 3 '-end and was prepared as per the method of Example 4 in Application Serial Number 782,374 utilizing 2'-O-methyl phosphoramidite intermediates as identified in Example 1(C).
  • the fourth test compound was a 2'-O-Me oligonucleotide of a second sequence:
  • Oligomer 46 (SEQ ID NO: 11): GAG CUC CCA GGC
  • each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group.
  • the fifth test compound was of sequence:
  • Oligomer 47 5' -CHA GAG CUC CCA GGC
  • CHA represents cholic acid and where each of the nucleotides of the oligonucleotide includes a 2'-O-methyl substituent group. It was of the same sequence as the fifth test compound.
  • This test compound included cholic acid conjugated to its 5'-end and was prepared as per the method of Example 3 in Application Serial Number 782,374 utilizing 2'-O-methyl phosphoramidite intermediates as identified in Example 1(C).
  • a sixth test compound was a randomized oligonucleotide of the sequence: Oligomer 48 (SEQ ID NO: 12): CAU GCU GCA GCC.
  • HeLa cells were seeded at 4 ⁇ 10 5 cells per well in 6-well culture dishes. Test oligonucleotides were added to triplicate wells at 1 ⁇ M and allowed to incubate at 37°C for 20 hours. Medium and oligonucleotide were then removed, cells washed with PBS and the cells were CaPO 4 transfected.
  • pHIVluc a plasmid expressing the luciferase cDNA under the transcriptional control of the HIV LTR constructed by ligating the Kpnl/Hindlll restriction fragments of the plasmids pT3/T71uc and pHIVpap (NAR 19(12)) containing the luciferase cDNA and the HIV LTR respectively, and 6 ⁇ g of pcDEBtat, a plasmid expressing the HIV tat protein under the control of the SV40 promoter, were added to 500 ⁇ l of 250 mM CaCl 2 , then 500 ⁇ l of 2x HBS was added followed by vortexing.
  • 2',3'-O-Dibutyl stannylene-uridine was synthesized according to the procedure of Wagner et. al . , J. Org. Chem. , 1974, 39, 24. This compound was dried over P 2 O 5 under vacuum for 12 hours. To a solution of this compound (29 g, 42.1 mmols) in 200 ml of anhydrous DMF were added (16.8 g, 55 mmols) of 6-bromohexyl phthalimide and 4.5 g of sodium iodide and the mixture was heated at 130°C for 16 hours under argon.
  • the 5'-O-(dimethoxytrityl)-3'-O-[hexyl-( ⁇ -N-phthalimidoamino]uridine-2'-O-succinyl-aminopropyl controlled pore glass was used to synthesize the oligomers 5'-GACU*-3' and 5'- GCC TTT CGC GAC CCA ACA CU*-3' (SEQ ID NO: 13) (where the * indicated the derivatized nucleotide) in an ABI 380B DNA synthesizer using phosphoramidite chemistry standard conditions. 45 and 200 O.D.'s of the 4-mer and 20-mer, respectively, were obtained from two and three 1 ⁇ mol syntheses after purification by RP-HPLC and desalting.
  • the oligomer 5'-GACU * -3' was used to confirm the structure of 3 ' -O-hexylamine tether introduced into the oligonucleotide by NMR. As expected a multiplet signal was observed between 1.0-1.8 ppm in 1 H NMR.
  • the oligomer 5' -GCC TTT CGC GAC CCA ACA CU * - 3' belongs to a HCV sequence and it was used to show the nuclease resistance properties of the 3'-O-amino tether [see example 39].
  • Example 7 The procedure of Example 7 was repeated, except that 5'-O-(dimethoxytrityl)-3'-O-[hexyl-( ⁇ -N-phthalimido-amino)]uridine was used as the starting material.
  • the aqueous layer was washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl.
  • the aqueous layer was washed with dichloromethane and the combined organic layers dried over MgSO 4 and concentrated.
  • the residue was chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate.
  • the desired product (0.83 grams, 58%) eluted with 100% ethyl acetate (R f 0.46 by thin-layer chromatography (TLC)).
  • 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(1-pyrene-propylcarbonyl)amino]uridine (1.0 g) was dissolved in 20 mL CH 2 Cl 2 and kept in ice-bath for 10 minutes. To the cold solution, 5 mL of 80% acetic acid in water was added and the solution was left to stand for 30 minutes. It was then evaporated to dryness and loaded into a silica column and eluted with 10% methanol in methylene chloride to give 2'-O-[hexyl-N-(1-pyrene-propyl-carbonyl)amino]uridine.
  • Example 12 The procedure of Example 12 is repeated, except that 5'-O-dimethoxytrityl-3'-O-[hexyl-N-(1-pyrene propyl carbonyl] amino] uridine is used.
  • Fluorescein isothiocyanate (Isomer I, available from Cal Biochem, La Jolla, CA) was treated with 12 equivalents of pivaloyl chloride in Et 3 N/THF to give di-O-pivaloyl fluorescein isothiocyanate. This compound was purified in silica gel column using 3:1 hexane:ethyl acetate. Nucleoside 5'-O-(dimethoxytrityl)-2'-O-(hexylamino)uridine was then condensed with dipivolyl fluorescein isothiocyanate in CH 2 Cl 2 /pyrimidine.
  • the resultant compound 5'-O- (dimethoxytrityl)-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-dipivolylfluorescein)amino]uridine is then purified by using 100% ethyl acetate, in a silica column.
  • the reaction mixture was then concentrated in vacuo and the residue dissolved in dichloromethane (75 mL) followed by washing with an equal volume of saturated ⁇ aHCO 3 .
  • the aqueous layer was washed with dichloromethane (50 mL) and the combined organic layers washed with an equal volume of saturated NaCl .
  • the aqueous layer was washed with dichloromethane (50 mL) and the combined organic layers dried over MgSO 4 and concentrated.
  • the residue was chromatographed on a silica gel column, eluting with a gradient of 25% ethyl acetate in hexanes to 100% ethyl acetate.
  • the desired product (670 mg, 77% yield, R f 0.79 by TLC) eluted with 100% ethyl acetate.
  • CPG aminopropyl controlled pore glass
  • CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG then is dried under vacuum, suspended in 15 mL piperidine and shaken 30 minutes. CPG is filtered off, washed thoroughly with dichloromethane, and again dried under vacuum. The extent of loading is then determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm.
  • Nucleoside 5'-O-(dimethoxytrityl)-2'-O-[hexylamino]-uridine (3.85 g, 6.0 mmol) was dissolved in anhydrous pyridine/dichloromethane 50/50 (v/v) (20 mL).
  • Cholesteryl chloroformate (Fluka, 3.0 g, 6.68 mmol) was dissolved in anhydrous dichloromethane (20 ml) and added slowly under argon with a syringe to the stirring reaction mixture. The mixture was stirred under argon at room temperature for 2 h after which it was concentrated in vacuo . Residual DMF was coevaporated with toluene.
  • Nucleoside 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)amino]uridine (3.44 g, 3.3 mmol) was dissolved in dry dichloromethane (75 mL).
  • 2-cyanoethyl N, N, N'N' -tetraisopropylphosphorodiamidite (Sigma, 2.1ml, 6.6 mmol)
  • diisopropylamine tetrazolide (0.29 g, 1.7 mmol) were added to the mixture, which was stirred under argon for 16 H.
  • Pentachlorophenol (0.03 grams, 0.11 mmol) is added and the mixture shaken 9 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG is then dried under vacuum, suspended in 10 ml piperidine and shaken 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm as approximately 39 ⁇ mol/g. EXAMPLE 20
  • Pentachlorophenol (0.045 grams, 0.16 mmol) is added and the mixture shaken 18 hours. CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane. CPG then is dried under vacuum, suspended in 15 ml piperidine and shaken for 15 minutes. CPG is filtered off, washed thoroughly with dichloromethane, and again dried under vacuum. The extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm, as approximately 29 ⁇ mol/gm.
  • N ⁇ ,Nimid-Di-FMOC-L-histine pentafluorophenyl ester (2.4 g, 3.1 mmol, purchased from Sigma) and 1-hydroxybenzotriazole (0.32 g, 0.24 mmol, purchased from Fluka) were added to the stirred reaction mixture stirred under argon. After 15 minutes, the ice bath was removed and the mixture stirred under argon at room temperature for 72 h.
  • Nucleoside 5'-O-(dimethoxytrityl)-2'-O-[hexylamino]-uridine (1 g, 1.55 mmol) is dissolved in anhydrous DMF (15 mL).
  • 1-Hydroxybenzotriazole (0.24 g, 1.75 mmol) and polyethylene glycol-propionic acid-NHS-ester (1.23 g, 1.75 mmol) are added to the reaction mixture.
  • the mixture is stirred under argon at room temperature for 2 hours after which it is concentrated in vacuo . Residual DMF is coevaporated with toluene.
  • the residue is dissolved in dichloromethane (50 mL) and then washed with an equal volume saturated NaHCO 3 .
  • the aqueous layer is washed with dichloromethane and the combined organic extracts washed with an equal volume saturated NaCl.
  • the aqueous layer is washed with dichloromethane and the combined organic layers dried over MgSO 4 and concentrated.
  • the residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate.
  • the desired product (1.08 g, 58%) eluted with 100% ethyl acetate.
  • the solution is washed with an equal volume of saturated NaHCO 3 .
  • the aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers washed with an equal volume of saturated NaCl.
  • the aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers dried over MgSO 4 and concentrated.
  • the residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate.
  • the desired product elutes with 100% ethyl acetate.
  • CPG controlled pore glass
  • 5'-O-(dimethoxytrityl)-2'-O-(hexylamine)uridine is treated as per the procedure of Example 3 with the macrocycle 4- ⁇ 1,4,8,11-tetraza-[tri-(trifluoroacetyl)cyclotetradec-1-yl] ⁇ methyl benzoic acid-N-hydroxy succinimide ester (prepared according to Simon Jones, et. al . , Bioconjugate Chem. 1991, 2, 416) to yield the product.
  • the nucleoside product of Example 29 is treated as per the procedure of Example 4 to yield the product.
  • the nucleoside product of Example 29 is treated as per the procedure of Example 5 to yield the product.
  • the nucleoside product of Example 32 is treated as per the procedure of Example 5 to yield the product.
  • the reaction mixture is then concentrated in vacuo and the residue dissolved in dichloromethane (75 mL) .
  • the solution is washed with an equal volume of saturated ⁇ aHCO 3 .
  • the aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers washed with an equal volume of saturated NaCl.
  • the aqueous layer is washed with dichloromethane (20 mL) and the combined organic layers dried over MgSO 4 and concentrated.
  • the residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 92% ethyl acetate.
  • the desired product elutes with 100% ethyl acetate.
  • nucleoside 0.025 grams
  • Pentachlorophenol 0.045 grams, 0.17 mmol
  • CPG is filtered off and washed successively with dichloromethane, triethylamine, and dichloromethane.
  • CPG is then dried under vacuum, suspended in 15 ml piperidine and shaken 15 minutes.
  • CPG is filtered off, washed thoroughly with dichloromethane and again dried under vacuum.
  • the extent of loading is determined by spectrophotometric assay of dimethoxytrityl cation in 0.3 M p-toluenesulfonic acid at 498 nm. to be approximately 27 ⁇ mol/g.
  • the aqueous layer is washed with dichloromethane and the combined organic layers dried over MgSO 4 and concentrated.
  • the residue is chromatographed on a silica gel column, eluting with a gradient of 50% ethyl acetate in hexanes to 100% ethyl acetate.
  • the desired product (0.15 grams, 80%) elutes with 10% Methanol-90% ethyl acetate.
  • 3'-O-Hexyl-(N-phthalimido)-aminouridine-CPG i.e. the 5'-O-dimethoxytrityl-3'-O-[hexyl-( ⁇ -N-phthalimidoamino)]-uridine-2'-O-(succinyl-aminopropyl) controlled pore glass from Example 5, was used to synthesize the following oligonucleotides:
  • Oligomer 50 GCC TTT CGC GAC CCA ACA CU
  • Oligomer 51 GCC TTT CGC GAC CCA ACA CU* wherein "*" denotes the 3'-0 hexylamino-modified nucleoside. Standard commercial phosphoramidites were used with the synthesis cycle times specified by the manufacturer in a 380B
  • Oligomer 49 was used for structural proof of 3'-O-alkylamine-bearing oligonucleotides at the 3 '-terminal end.
  • Oligomer 51 was used to demonstrate the nuclease resistance offered by this the alkylamino group and also for further conjugation.
  • the oligomer was treated with pyrenebutyric acid-N-hydroxy succinimide ester in 0.2 M NaHCO 3 buffer/DMF.
  • the product, Conjugate 1 was purified by HPLC and size exclusion methods. HPLC retention times (eluting with a gradient of 5% CH 3 CN for 10 minutes then 5%-40% CH 3 CN for 50 minutes) were as follows:
  • the nuclease stability of Oligomer 51 and the conjugate were tested against Oligomer 50 in HeLa cytoplasmic/nuclear extracts.
  • the cell extract was diluted 1.4 times.
  • the final concentration of oligonucleotide was 20 ⁇ M.
  • the half lives of the oligonucleotides were as follows:
  • Oligomer 52 (SEQ ID NO: 14): GCGTGU * CTGCG
  • HPLC retention times (eluting with a gradient of 5% CH 3 CN for 10 minutes then 5%-40% CH 3 CN for 50 minutes in a C- 18 Delta-Pak reverse phase column) were as follows:
  • T m Changes in T m due to pyrene conjugation were evaluated against both DNA and RNA.
  • T m was measured in 100 mM Na + , 10 nM phosphate, 0.1 mM EDTA, pH 7 at 4 ⁇ M strand concentration. The results were as follows:
  • Oligomer 55 GCC GU * G TCG
  • oligomers were purified trityl-on reverse-phase HPLC, detritylated in 80% acetic acid for one hour and then repurified by RP-HPLC and desalted by size-exclusion chromatography. NMR analysis showed the presence of pyrene peaks.
  • Theamidite 5'-O-(dimethoxytrityl)-2'-O-[hexyl-N-(2,4-dinitrophenyl)amino]uridine-3'-O-(2-cyanoethyl-N,N,-diisopropyl)phosphoramidite (0.18 M in anhydrous acetonitrile) was used to synthesize oligonucleotides, Oligomers 56 to 63. All are analogues of an ICAM antisense sequence.
  • oligomers were purified trityl-on by RP-HPLC (Waters Delta-Pak C 18 column, 300 A, 7.8 mm ⁇ 30 cm, linear 50-min gradient of 5-60% acetonitrile in 0.05 M TEAA pH 7.3), detritylated in 80% acetic acid for one hour and then purified by RP-HPLC and desalted by size-exclusion chromatography. Data are summarized below:
  • the amidite 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(3-oxycarbonyl-cholesteryl)amino]uridine-3'-O-[2-cyanoethyl-N,N,-diisopropyl]-phosphoramidite (0.2M in anhydrous aceto- nitrile/dichloromethane 2:1 v/v) was used to synthesize Oligomers 67-74.
  • oligomers are purified trityl-on by reverse-phase HPLC (Waters Delta-Pak C 18 , 300A, 7.8 mm ⁇ 30 cm, linear 55-min gradient of 5-80% acetonitrile in 0.05 M TEAA pH 7.3), detritylated in 80% acetic acid for one hour and then repurified by RP-HPLC and desalted by size-exclusion chromatography. Data are summarized below: Backbone Target Retention
  • the amidite 5'-O-dimethoxytrityl-2'-O-[hexyl-N-(5-thiocarbonyl-3,6-dipivolyl fluorescein)amino]uridine-3'-O- (cyanoethyl-N,N-diisopropyl phosphoramidite) (0.2 M in anhydrous acetonitrile) was used to synthesize Oligomer 74 (above) and Oligomers 75-82 on a 1 ⁇ 10 5 (Oligomer 75) or 1 ⁇ 10 2 (remaining Oligomers) ⁇ mol scale.
  • oligomers are purified trityl-on by reverse phase HPLC (Waters Delta-Pak C 18 , 300A, 7.8 mm ⁇ 30 cm, linear gradient of acetonitrile in 0.05 M TEAA pH 7.3), detritylated in 80% acetic acid for one hour and then repurified by RP-HPLC and desalted by size-exclusion chromatography.
  • reverse phase HPLC Waters Delta-Pak C 18 , 300A, 7.8 mm ⁇ 30 cm, linear gradient of acetonitrile in 0.05 M TEAA pH 7.3
  • Oligomer 81 (SEQ ID NO: 26)
  • oligonucleotides were deprotected and purified using the procedure described in Example 2. Table I summarizes the different oligonucleotides along with their HPLC retention times.
  • HPLC conditions Waters DeltaPak C-18 Delta Pak reverse- phasel5m 300 A column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50mM TEAA, pH 7.0.; Solvent B: acetonitrile; Gradient: 0-10 min., 5% acetonitrile; 10-60 min., 5% to 60% acetonitrile linear increase.
  • DMAP (0.005 g, 40 ⁇ mol) and 5'-O-(dimethoxytrityl)-3'-O-[hexyl-N-(N-biotinyl-6-aminocaproyl)amino]uridine (0.22 g, 0.22 mmol) were added under argon and the mixture shaken mechanically for 19 hours. More nucleoside (0.025 g) was added and the mixture shaken for an additional 5.5 hours. Pentachlorophenol (0.045 g, 0.168 mmol) was add and the mixture shaken for 18 hours.
  • the oligonucleotides were deprotected and purified using the procedure described in Example 2.
  • the controlled pore glass containing biotin was used to synthesize 3 '-biotin containing oligonucleotides.
  • 1,2-Di-O-hexadecyl-rac-glycerol (2g, 3.69 mmol) was dissolved in 3 mL of CH 2 Cl 2 and to this solution disuccinimidyl carbonate (DSC) (1.42 g, 5.54 mmol) was added. Triethylamine was then added (2 mL, 14.3 mmol), followed by 20 mL of anhydrous acetonitrile. The reaction flask was saturated with argon, sealed and then shaken in a wrist action shaker. After 8 hours the reaction mixture was evaporated.
  • DSC disuccinimidyl carbonate
  • the lipid-uridine nucleoside from the previous step was dissolved in 20 mL of CH 2 Cl 2 .
  • 200 mg of diisopropylaminotetrazolide (1.16 mmol) was added followed by 1.55 mL of 2-cyanoethyl-N,N,N',N'-tetraisopropyl phosphoramidite (4.75 mmol) was added under argon atmosphere.
  • the mixture was stirred under argon overnight after which time TLC (5% CH 3 OH/CH 2 Cl 2 ) indicated almost complete conversion of nucleoside to its phosphoramidite.
  • the reaction mixture was washed with saturated NaHCO 3 followed by saturated NaCl solution and then dried over anhydrous MgSO 4 .
  • the solution was evaporated and the foamy residue was purified in a silica column using 5% CH 3 OH/CHCl 3 elution system to give the purified phosphoramidite.
  • oligonucleotides were deprotected and purified using the procedure described in Example 2.
  • the Table below summarizes the different oligonucleotides (ICAM, ras, raf and PKC-a oligonucleotides).
  • IAM oligonucleotides
  • ras oligonucleotides
  • PKC-a oligonucleotides PKC-a oligonucleotides
  • HPLC conditions Waters DeltaPak C-4 Delta Pak reverse-phase15m 300 A column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50mM TEAA, pH 7.0.; Solvent B:
  • Oligonucleotides were synthesized on an Expedite Nucleic Acid Synthesis System (Millipore Corp., Bedford, MA) . Two 1- ⁇ mol syntheses or a single 15 ⁇ mol synthesis was performed for each oligonucleotide. Standard DNA synthesis conditions were used except during coupling of the modified amidite which was accomplished as follows: The novel amidite was dissolved in CH 2 Cl 2 /CH 3 CN 50/50 (0.08-0.1M). For 10 ⁇ mol syntheses, a 6-min wait step was added to the coupling cycle, which was repeated once. For 1 ⁇ mol phosphodiester syntheses, the coupling step was also extended for 6 min, with periodic addition of fresh amidite. For 1 ⁇ mol phosphorothioate syntheses, the coupling step was extended for 13 min, with periodic addition of fresh amidite .
  • oligonucleotides were trityl-on purified by preparative HPLC to remove failure sequences.
  • HPLC conditions Waters Delta-Pak C 4 column, 7.8 mm ⁇ 30 cm, 300 A, 15 u; 2.5 ml/min flow rate using a gradient of 5-80% AcCN in 50mM triethylammonium acetate pH 7.0 over 50 min.
  • oligonucleotides were detritylated for 45 min in 80% acetic acid and lyophilized again. Oligonucleotides were then further purified by size exclusion on G-25 columns to remove salts and the trityl group.
  • oligonucleotides were analyzed by HPLC using a gradient analogous to the one above and a Waters Delta-Pak C 4 column (3.9 mm x 30 cm) with a flow rate of 1.5 ml/min over 50 min. 8002 was analyzed using a gradient of 5-60% AcCN. Purified phosphorothioate oligonucleotides appeared as two peaks by HPLC, phosphodiesters as one peak. Oligonucleotides were further analyzed by electrophoresis on 20% polyacrylamide denaturing (7M urea) gels. All were predominantly single bands of the appropriate size compared to standards. Gel analysis of 8012 (loaded without any pretreatment) shows a very high band, presumably the tetrameric form of this oligonucleotide, plus a faint band where one would expect a monomeric 8mer+cholesterol to run.
  • the parent compound, 5320 is known to form a G-quartet structure.
  • Some oligonucleotides were also analyzed by capillary electrophoresis. Selected oligonucleotides have been analyzed by electrospray mass spectrometry.
  • Oligonucleotides incorporating 2'-O-(CH 2 ) 6 -NHCO-cholesterol at nonterminal were synthesized at a 1 ⁇ mol syntheses scale, analyzed and purified as per the procedures of Example 65.
  • Example 65 except that standard DNA synthesis conditions were used for all couplings.
  • Example 65 except that the extended coupling step for the cholesterol amidite (see Example 65) was repeated once.
  • the parent oligonucleotide complementary to messenger RNA of PKC ⁇ , is a chimeric phosphorothioate oligonucleotide having a central deoxyribonucleotide region that is "flanked" on both the 5' and the 3' sides with region that have 2'-deoxy-2'-fluoro nucleotides. These compound are alternately referenced as “gapped” oligonucleotides. The central "gapped" regions are shown in underlines in the Table below with the "flanks" (or alternatively the "wings") shown in unmodified type.
  • the oligonucleotides were synthesized, analyzed and purified as in Example 65, except for the following: Concentration of all amidites was 0.1 M. Two l- ⁇ mol syntheses were performed for each oligonucleotide. The coupling step was extended 6 min, with periodic addition of fresh amidite; this extended coupling step was repeated once for the cholesterol amidite coupling. Trityl-on HPLC purification of Compound ID #9532 was accomplished using a linear gradient of 5-40% AcCN over 50 min. After detritylation and purification by size-exclusion, it was analyzed using a similar analytical-scale HPLC procedure gel and capillary electrophoresis. Purified compound ID #9535 appears as two peaks by HPLC, others as one peak. Compound ID#s 9532 and 9534 contained undeprotected 3'-hexylamine; probably about 20% according to previous results (phthalimide is the protecting group).
  • reaction mixture was transferred with CH 2 Cl 2 and washed with saturated NaHCO 3 (100 mL), followed by saturated NaCl solution.
  • the organic layer was dried over anhydrous Na 2 SO 4 and evaporated to yield 3.8 g of a crude product, which was purified in a silica column (200 g) using 1:1 hexane/EtOAc to give 1.9 g (1.95 mmol, 74% yield) of the desired phosphoramidite.
  • the oligonucleotides 9274 and 9518 (20 ODs each) were dried and re-dissolved in 0.2M NaHCO 3 buffer (200 ⁇ L) in an eppendorf tube. 5 mg of pyrene butyric acid-N-hydroxy succinimide ester was dissolved in 400 ⁇ L anhydrous DMF. 200 ⁇ L of this solution was added to each of the eppendorf tubes and vortexed and left to stand overnight. The reaction mixtures were passed through a g-25 column to remove the excess reagent, an then purified by Reverse-Phase HPLC. The retention times of the starting material and the conjugates are summarized below: Sequence (3' ⁇ 5') Retention Time
  • HPLC conditions Waters DeltaPak C-18 Delta Pak reverse- phase15m 300 ⁇ column, 3.9x 300 mm size equipped with C-18 guard column; Solvent A: 50mM TEAA, pH 7.0.; Solvent B: acetonitrile; Gradient: 0-10 min., 5% acetonitrile; 10-60 min., 5% to 40% acetonitrile linear increase.
  • Oligonucleotide 31-A is a normal 3' -5' linked phosphodiester oligodeoxyribonucleotide of the sequence d(GGC
  • TGU* CTG CG) (SEQ ID NO: 37) where the * indicates the attachment site of either a 2'-aminolinker or a 2'-aminolinker plus pyrene.
  • Oligonucleotide 31-B is a normal 3 '-5' linked phosphodiester oligoribonucleotide of the sequence d(GGC TGU* CTG CG) where the * indicates the attachment site of either a 2'-aminolinker or a 2'-aminolinker plus pyrene.
  • Each of the ribonucleotides of the oligonucleotide, except the one bearing the * substituent, are 2'-O-methyl ribonucleotides.
  • Oligonucleotide 31-C is has 2' -5' linkage at the * position in addition to either a 3'-aminolinker or a 3'-aminolinker plus pyrene at this site.
  • the remainder of the oligonucleotide is a phosphodiester oligodeoxyribonucleotide of the sequence d(GGC TGU* CTG CG).
  • the 2' -5' linkages demonstrated a higher melting temperature against an RNA target compared to a DNA target .
  • 4,4'-Dimethoxytrityl chloride (3.6 g, 10.0 mmol.) was added to a solution of N 6 -(dibenzoyl)-2'-O-[3-(N-trifluoroacetamido) propyl) adenosine in pyridine (100 ml) at room temperature and stirred for 16 hrs. The solution was concentrated in vacuo and chromatographed on silica gel (EtOAc/TEA 99/1) to give the title compound.
  • the title compound was prepared as per Example 75, using N- (5-bromopentyl) phthalimide.
  • the crude material from the extraction was chromatographed on silica gel using CHCl 3 /MeOH (95/5) to give a mixture of the 2' and 3' isomers.
  • the 2' isomer was recrystallized from EtOH/MeOH 8/2.
  • the mother liquor was rechromatographed on silica gel to afford the 3' isomer.
  • the resultant gum was chromatographed on silica gel (CHCl 3 /MeOH 9/1) to give 53.3 g of the 2' isomer (42%). Those fractions containing the 3' isomer were crystallized from EtOAc/MeOH to yield 20 g of the 3' isomer (16%).
  • 2-Amino-2'- O-(propylphthalimide)adenosine (38.6 g, 82 mmol) was dissolved in dimethylsulfoxide (DMSO, 1000 ml). Sodium phosphate (0.1 M, 63 ml) and Tris buffer (0.5 M, 1200 ml) were added with stirring. The solution was adjusted to pH 7.0 with phosphoric acid. Adenosine deaminase (Sigma, 1.7 g) was added and the temperature raised to 35°C. The solution was stirred for 4 days with an additional aliquot of adenosine deaminase (0.2 g) added every 24 hrs. The solution was maintained at pH 7.0 with the addition of phosphoric acid.
  • the title compounds are prepared as per Example 111 with the substitution of 2-aminoadenosine for adenosine.
  • the isomer ratio of 2'/3' was 74/26.
  • Tm Melting temperatures for a variety of modified oligonucleotides according to the invention were determined according the method set forth in Procedure B(1) (b). The resulting data is shown in Tables 5-8, wherein all listed oligonucleotides contain 2'-deoxy sugars and phosphodiester backbones unless otherwise indicated.
  • Table 5 shows changes in Tm that result by modifying the 2 '-position of adenosine nucleotides to include a variety of substituent groups.
  • the first entry shows that the introduction of 2'-O-aminopropyl adenosine substituents at two adenosine nucleotides resulted in a heteroduplex having a Tm that is 1.13°C greater than the heteroduplex formed by an unmodified oligonucleotide having the same sequence.
  • Table 6 shows changes in Tm that result by modifying one or more 2'- and 3 '-positions of the indicated parent oligonucleotides to include linkers and pyrene conjugates. These modifications were made to terminal and internal (i.e., non-terminal) positions within the oligonucleotide.
  • the notation "PS” indicates the presence of a phosphorothioate backbone, and the notation “2'-5' linkage” indicates 2'-5' intersugar linkages.
  • Tables 7a-c show changes in Tm that result by modifying one or more positions of the indicated parent oligonucleotides to include linkers and cholate or cholesterol conjugates.
  • the introduction of an aminolink linker at the 3'-position of a single terminal nucleotide of the parent phosphorothioate oligonucleotide resulted in a Tm increase of 1.3°C and the addition of a cholate group to the linker resulted in a further Tm increase of 1.1°C.
  • Table 8 shows changes in Tm that result by modifying one or more 3'-positions of the indicated parent oligonucleotides to include linkers and PEG conjugates.
  • the entries under the heading "PEG vs Unmodified" represent preliminary findings. As can be seen, the first entry indicates that introduction of an aminolink linker at the 3'-position of a single terminal nucleotide of the parent phosphodiester oligonucleotide resulted in a Tm increase of 0.9°C and that the addition of a PEG 550 group to the linker did not change the Tm of the resulting product.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne des nucléosides et des oligonucléosides modifiés par l'adjonction de fonctions alkylamino, ainsi que leurs dérivés. Dans certaines formes d'exécution, les composés de l'invention comportent en outre des stéroïdes, des molécules reporteurs, des enzymes reporteurs, des molécules lipophiles, des peptides ou des protéines, fixés aux nucléosides par le groupe alkylamino.
PCT/US1994/010131 1990-01-11 1994-09-02 Nucleosides et oligonucleosides a fonction(s) amine Ceased WO1995006659A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
AT94928048T ATE247128T1 (de) 1993-09-03 1994-09-02 Aminoderivatisierte nukleoside und oligonukleoside
DE69433036T DE69433036T2 (de) 1993-09-03 1994-09-02 Aminoderivatisierte nukleoside und oligonukleoside
AU77233/94A AU679566B2 (en) 1993-09-03 1994-09-02 Amine-derivatized nucleosides and oligonucleosides
CA002170869A CA2170869C (fr) 1993-09-03 1994-09-02 Derives amines de nucleosides et d'oligonucleosides
US08/602,862 US7037646B1 (en) 1990-01-11 1994-09-02 Amine-derivatized nucleosides and oligonucleosides
EP94928048A EP0728139B1 (fr) 1993-09-03 1994-09-02 Nucleosides et oligonucleosides a fonction(s) amine
JP50832695A JP3484197B2 (ja) 1993-09-03 1994-09-02 アミン誘導化ヌクレオシドおよびオリゴヌクレオシド
US09/435,806 US6653458B1 (en) 1993-09-03 1999-11-08 Modified oligonucleotides

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85463492A 1992-07-01 1992-07-01
US08/117,363 1993-09-03
US08/117,363 US6783931B1 (en) 1990-01-11 1993-09-03 Amine-derivatized nucleosides and oligonucleosides

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/117,363 Continuation-In-Part US6783931B1 (en) 1990-01-11 1993-09-03 Amine-derivatized nucleosides and oligonucleosides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US08/602,862 Continuation-In-Part US7037646B1 (en) 1990-01-11 1994-09-02 Amine-derivatized nucleosides and oligonucleosides

Publications (1)

Publication Number Publication Date
WO1995006659A1 true WO1995006659A1 (fr) 1995-03-09

Family

ID=26815203

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/010131 Ceased WO1995006659A1 (fr) 1990-01-11 1994-09-02 Nucleosides et oligonucleosides a fonction(s) amine

Country Status (1)

Country Link
WO (1) WO1995006659A1 (fr)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0724447A4 (fr) * 1991-10-24 1996-01-22 Isis Pharmaceuticals Inc Oligonucleotides derives presentant diverses qualites dont une meilleure facilite d'absorption
US5594117A (en) * 1994-08-25 1997-01-14 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties and associated methods of synthesis and use
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
EP0831854A4 (fr) * 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate
EP0983291A4 (fr) * 1996-09-13 2001-04-04 Isis Pharmaceuticals Inc Nucleosides et oligonucleosides derives de carbamate
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
WO2001008707A3 (fr) * 1999-07-28 2001-11-08 Aventis Pharma Gmbh Conjugats et procedes permettant de les preparer, et leur utilisation pour transporter des molecules par l'intermediaire de membranes biologiques
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6670468B1 (en) 1996-06-06 2003-12-30 Novartis Ag 2′-substituted nucleosides and oligonucleotide derivatives
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US12005074B2 (en) 2018-05-07 2024-06-11 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4910300A (en) * 1985-12-11 1990-03-20 Chiron Corporation Method for making nucleic acid probes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCIENCE, Vol. 238, issued 04 December 1987, COREY et al., "Generation of a Hybrid Sequence-Specific Single Stranded Deoxyribonuclease", pages 1401-1403. *
See also references of EP0728139A4 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6465188B1 (en) 1990-06-11 2002-10-15 Gilead Sciences, Inc. Nucleic acid ligand complexes
US6011020A (en) * 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6147204A (en) * 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
EP0724447A4 (fr) * 1991-10-24 1996-01-22 Isis Pharmaceuticals Inc Oligonucleotides derives presentant diverses qualites dont une meilleure facilite d'absorption
US5594117A (en) * 1994-08-25 1997-01-14 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties and associated methods of synthesis and use
US5597909A (en) * 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US8071737B2 (en) 1995-05-04 2011-12-06 Glead Sciences, Inc. Nucleic acid ligand complexes
US5859228A (en) * 1995-05-04 1999-01-12 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
EP0831854A4 (fr) * 1995-06-06 2001-01-24 Isis Pharmaceuticals Inc Oligonucleotides de grande purete chirale ayant des liaisons phosphorothioate
US7879993B2 (en) 1995-06-07 2011-02-01 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6582918B2 (en) 1995-06-07 2003-06-24 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
US5744460A (en) * 1996-03-07 1998-04-28 Novartis Corporation Combination for treatment of proliferative diseases
US6670468B1 (en) 1996-06-06 2003-12-30 Novartis Ag 2′-substituted nucleosides and oligonucleotide derivatives
EP0983291A4 (fr) * 1996-09-13 2001-04-04 Isis Pharmaceuticals Inc Nucleosides et oligonucleosides derives de carbamate
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US6962784B2 (en) 1996-10-25 2005-11-08 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6051698A (en) * 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US7939654B2 (en) 1997-12-16 2011-05-10 Gilead Sciences, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
HRP20020074B1 (en) * 1999-07-28 2011-01-31 Sanofi-Aventis Deutschland Gmbh Conjugates and methods for the production thereof, and their use for transporting molecules via biological membranes
KR100721696B1 (ko) * 1999-07-28 2007-05-28 사노피-아벤티스 도이칠란트 게엠베하 분자를 생물학적 막을 통해 수송하기 위한 접합체 및 이의 제조방법
RU2275936C2 (ru) * 1999-07-28 2006-05-10 Санофи-Авентис Дойчланд Гмбх Конъюгаты и способ их получения, а также их применение для транспорта молекул через биологические мембраны
JP2003505517A (ja) * 1999-07-28 2003-02-12 アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用
JP4791665B2 (ja) * 1999-07-28 2011-10-12 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 接合体ならびにそれらの製造方法および生体膜を横切り分子を輸送するためのそれらの使用
WO2001008707A3 (fr) * 1999-07-28 2001-11-08 Aventis Pharma Gmbh Conjugats et procedes permettant de les preparer, et leur utilisation pour transporter des molecules par l'intermediaire de membranes biologiques
US8420396B2 (en) 1999-07-28 2013-04-16 Sanofi-Aventis Deutschland Gmbh Conjugates and processes for their preparation and their use for transporting molecules across biological membranes
US8853376B2 (en) 2002-11-21 2014-10-07 Archemix Llc Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics
US12005074B2 (en) 2018-05-07 2024-06-11 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery
US12397013B2 (en) 2018-05-07 2025-08-26 Alnylam Pharmaceuticals, Inc. Extrahepatic delivery

Similar Documents

Publication Publication Date Title
EP0728139B1 (fr) Nucleosides et oligonucleosides a fonction(s) amine
US7037646B1 (en) Amine-derivatized nucleosides and oligonucleosides
US6783931B1 (en) Amine-derivatized nucleosides and oligonucleosides
US6111085A (en) Carbamate-derivatized nucleosides and oligonucleosides
EP0716604B1 (fr) Nucleosides et oligonucleosides a fonction(s) thiol
US6753423B1 (en) Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
WO1995006659A1 (fr) Nucleosides et oligonucleosides a fonction(s) amine
EP0724447B1 (fr) Oligonucleotides derives presentant une meilleure facilite d'absorption
EP0882061B1 (fr) Oligonucléotides lacunaires ayant des sucres modifiés
US6153737A (en) Derivatized oligonucleotides having improved uptake and other properties
US6172209B1 (en) Aminooxy-modified oligonucleotides and methods for making same
AU2003213150A2 (en) Method of using modified oligonucleotides for hepatic delivery
JP2001097994A (ja) ２’−ｏ−置換ピリミジンおよびそのオリゴマー化合物の合成の改良法
JP2001512457A (ja) アミノオキシ修飾オリゴヌクレオチド
US6114513A (en) Thiol-derivatized oligonucleotides
US5852182A (en) Thiol-derivatized oligonucleosides
US6653458B1 (en) Modified oligonucleotides
Pandolfi et al. Evaluation of different types of end-capping modifications on the stability of oligonucleotides toward 3′-and 5′-exonucleases
US20040142899A1 (en) Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
WO2000004189A1 (fr) Oligonucleotides modifies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA US US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE MW SD AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08602862

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2170869

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1994928048

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994928048

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994928048

Country of ref document: EP